GMOs

First Senate Agricultural Committee Meeting in 10 Years Cheers GMOs, Ignores Dangers

The U.S. Senate Committee on Agriculture, Nutrition, and Forestry held a biotechnology hearing for the first time in 10 years last week to discuss the future of food technology as the industry responds to increased demand, production challenges, and consumers’ calls for a safe and transparent food supply. But the meeting came up short on transparency and carried on more like a Monsanto share-holders meeting than an unbiased inquiry into the pros and cons of biotechnology where it concerns the food supply.

Biotech Stocks Tumble After Major Corp Dubbed “Pharmaceutical Enron”

GM and biotech companies responsible for inflated pharmaceutical prices were already taking a beating on the stock market, but after the latest report from Citron Research classifying Valeant Pharmaceuticals Intl Inc as a “pharmaceutical Enron,” the whole sector has come tumbling down like the house of cards it truly is.